Current off-label Pharmacotherapeutics in the management of novel coronavirus disease (COVID-19)
Current off-label Pharmacotherapeutics in the management of novel coronavirus disease (COVID-19)
复制标题
目前治疗新型冠状病毒疾病（COVID-19）的标签外药物治疗
DOI：
10.37881/1.511
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
A. Pathan
中科院分区：
文献类型：
--
作者：
A. Pathan
2019 冠状病毒病 (COVID-19) 是由一种新出现的冠状病毒（严重急性呼吸综合征 SARS-CoV-2）引起的呼吸道感染，该病毒于 2019 年 12 月在中国武汉首次发现。目前尚无 FDA 批准的治疗、治愈或预防 COVID-19 的疗法或药物。一些报告的案例研究表明，氯喹在轻症病例中使用的重要性，洛匹那韦和利托那韦在重症病例中的重要性分别。印度医学研究理事会发布了一项协议，当印度患者疑似感染 COVID-19 时，该协议将与世界卫生组织关于轻度和重度急性呼吸道感染临床管理的指南一起实施，作为限制性公共卫生紧急用途。
Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, Severe acute respiratory syndrome SARS-CoV-2, that was first recognized in Wuhan, China, in December 2019. There are no FDA- approved therapeutics or drugs to treat, cure or prevent COVID-19. Some reported case studies indicated the significance of Chloroquine use in mild cases and Lopinavir and Ritonavir in severe cases of COVID-19 respectively. Indian Council of Medical Research, India issued a protocol which is to be implemented along with the WHO guidelines on clinical management of mild and severe acute respiratory infection when COVID-19 infection is suspected in Indian patients as a restricted public health emergency use.